...
首页> 外文期刊>Pediatric allergy and immunology: official publication of the European Society of Pediatric Allergy and Immunology >Increased glycosaminoglycans in the urine of asthmatic children on inhaled corticosteroids.
【24h】

Increased glycosaminoglycans in the urine of asthmatic children on inhaled corticosteroids.

机译:吸入糖皮质激素可使哮喘儿童尿液中的糖胺聚糖含量增加。

获取原文
获取原文并翻译 | 示例
           

摘要

Increased extracellular matrix (ECM) deposition in the airway wall contributes to the airway remodeling in asthmatics. Glycosaminoglycans (GAGs) are polysaccharides attached to a protein core in order to form proteoglycans, a component of the ECM. In this study, we investigated the possible influence of long-term treatment with inhaled corticosteroids (ICS) on urinary GAGs levels of asthmatic children. Seventy asthmatic children (41 boys), aged 6.8-12.5 yr, participated in the study. About 44 were treated with inhaled budesonide via turbuhaler for 2-35 months (median 12 months) and 26 were on relief medications. About 30 healthy controls were also studied. GAGs were precipitated from early morning urine samples, collected, isolated and quantified using uronic acid-carbazole reaction and expressed as uronic acid (UA) in microg/g/Cr(u)/m2. Urinary GAGs values did not differ significantly between controls and asthmatics but significant differences were found between children on ICS and asthmatics on relief medications (p < 0.001). There was a positive correlation between the daily dose of inhaled budesonide and the urinary GAGs values (r = 0.32, p = 0.037) whereas a threshold distinguishing 'low' vs. 'high' doses of ICS was found to be at 300 microg/m2 per day with a significant difference in urinary GAGs secretion (p = 0.006). Our data show that urinary GAGs secretion is reduced in asthmatic children that used only relief medication but it is increased in those on long-term treatment with ICS. A dose dependent effect of ICS was also detected.
机译:气道壁中增加的细胞外基质(ECM)沉积有助于哮喘患者的气道重塑。糖胺聚糖(GAGs)是附着在蛋白质核心上的多糖,以形成蛋白聚糖(ECM的一个组成部分)。在这项研究中,我们调查了长期吸入性糖皮质激素(ICS)治疗对哮喘儿童尿GAGs水平的可能影响。年龄为6.8-12.5岁的70名哮喘儿童(41名男孩)参加了这项研究。大约有44名患者通过turbuhaler吸入布地奈德治疗了2-35个月(中位数为12个月),有26例正在接受缓解药物治疗。还研究了约30名健康对照。 GAGs从清晨尿液样本中沉淀出来,使用尿酸-咔唑反应进行收集,分离和定量,并以微克/克/克(u)/平方米的尿酸(UA)表示。对照组和哮喘患者之间的尿GAGs值无显着差异,但接受ICS的儿童和接受缓解药物治疗的哮喘患者之间的尿GAG值存在显着差异(p <0.001)。布地奈德的每日吸入剂量与尿中GAGs值呈正相关(r = 0.32,p = 0.037),而将ICS的“低”剂量与“高”剂量区分开的阈值为300 microg / m2每天的尿GAGs分泌差异显着(p = 0.006)。我们的数据显示,仅使用缓解药物的哮喘儿童尿GAG的分泌减少,但长期接受ICS治疗的儿童尿GAG的分泌增加。还检测到ICS的剂量依赖性作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号